BOTHELL, WA, USA I April 05, 2024 I Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is taking place April 5-10 in San Diego, California.
“FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties,” commented Dr. Higgins. “We believe IM-3050 has best-in-class potential and look forward to sharing preclinical data for the program at AACR.”
Immunome expects to submit an Investigational New Drug application to the U.S. Food & Drug Administration for IM-3050 in the first quarter of 2025.
Poster Presentation Details:
Title: A novel lutetium-177 radioligand therapy targeting FAP has potent antitumor activity in xenograft cancer model (Abstract #6026)
Presenter: Jack Higgins, PhD, Chief Scientific Officer
Date: April 9, 2024 1:30 p.m. – 5:00 p.m. PDT
A copy of the poster will be available on the Events & Presentations section of Immunome’s website following the conference.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, RLTs and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.
SOURCE: Immunome
Post Views: 298
BOTHELL, WA, USA I April 05, 2024 I Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is taking place April 5-10 in San Diego, California.
“FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties,” commented Dr. Higgins. “We believe IM-3050 has best-in-class potential and look forward to sharing preclinical data for the program at AACR.”
Immunome expects to submit an Investigational New Drug application to the U.S. Food & Drug Administration for IM-3050 in the first quarter of 2025.
Poster Presentation Details:
Title: A novel lutetium-177 radioligand therapy targeting FAP has potent antitumor activity in xenograft cancer model (Abstract #6026)
Presenter: Jack Higgins, PhD, Chief Scientific Officer
Date: April 9, 2024 1:30 p.m. – 5:00 p.m. PDT
A copy of the poster will be available on the Events & Presentations section of Immunome’s website following the conference.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, RLTs and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.
SOURCE: Immunome
Post Views: 298
